The University of Colorado Cancer Center is a """"""""Center' within the School of Medicine at the University of Colorado Health Sciences Center. The Cancer Center goals are: 1) to contribute through coordinated research, clinical, control and educational activities effort to the eventual elimination of cancer as a human health problem, and 2) to provide the citizens of the State of Colorado and the Rocky Mountain region with state-of-the-art cancer research, therapy, control and educational programs. The Cancer Center serves 6 million people in Colorado and the 7 surrounding states in the Rocky Mountain region. The 190 Cancer Center members have more than $21 million (annual direct costs) in peer reviewed grants and contracts relating to the cancer problem. Cancer Center members provide care to approximately one-third of the cancer population in the region and enter more than 400 patients on cancer clinical trials each year. The Cancer Center enters an increasing number of patients of clinical trials emphasizing novel trials of the Center and high priority trials of the National Cancer Institute. The majority of cancer educational and control programs in the region are organized by Cancer Center members. The Center provides the major centralized support for these functions through its 10 shared """"""""core"""""""" facilities in Biostatistics, Clinical Investigations, Cytogenetics, Fermentation, Flow Cytometry, Histopathology/Tissue Procurement, Laboratory Animals/Transgenic Animals, Macromolecular Resources, Radiological Sciences and Tissue Culture/Monoclonal Antibodies. The Cancer Center has 14 institutional members including the Health Sciences Center schools, affiliated hospitals and other institutions with a primary focus in cancer. The chief executive officers of these organizations form the Cancer Center Board which assures coordination of the cancer effort in the region. The Cancer Center has four major program divisions: Basic Research, Clinical Activities, Education and Control. The Basic Research and Clinical Activities Divisions are divided into: Immunology; Molecular Biology; Growth Regulation; Cell Surface; Hormones and Cancer; Chromosomes, Mutation and Carcinogenesis; Medical Oncology; Surgical Oncology; Radiation Oncology; Nursing Oncology; and Pediatric Oncology program areas. The primary planning and operational decisions of the Cancer Center are made by the Management Committee which consists of the Director, Deputy Director, Associate Directors and Program Leaders. The University of Colorado Cancer Center has become the leader for the interdisciplinary study of cancer in the Rocky Mountain Region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-05
Application #
3101850
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1988-03-01
Project End
1995-02-28
Budget Start
1992-05-11
Budget End
1993-02-28
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363

Showing the most recent 10 out of 1634 publications